Danaher Corporation, a global life sciences and diagnostics innovator, announced its financial performance for the fourth quarter of 2025.
Estimated revenues for Q4 2025 are expected to increase in the mid-single digit percent range year-over-year.
Non-GAAP core revenue growth for Q4 2025 is projected to be toward the high-end of the previously announced low-single digit percentage guidance.
Danaher's strong finish in 2025 was driven by continued Bioprocessing strength and surpassing projections in Life Sciences and Diagnostics revenue in Q4. This performance is underpinned by the company's differentiated portfolio, the Danaher Business System, and its robust balance sheet, setting a foundation for sustained value creation in 2026 and beyond.
Revenue Growth
Danaher forecasts mid-single digit year-over-year revenue growth for Q4 2025.
Non-GAAP Core Revenue Growth
The company expects non-GAAP core revenue growth in Q4 2025 to align with the upper end of the initially communicated low-single digit range.
Earnings Per Share
Projected non-GAAP adjusted diluted net earnings per common share for full year 2025 anticipate reaching the higher segment of the guidance range of $7.70 to $7.80.
- Danaher's strong Q4 2025 results stem from the resilience in Bioprocessing and exceptional performance in the Life Sciences and Diagnostics segments during the quarter.
- The company's distinctive portfolio, coupled with the Danaher Business System and a solid financial position, positions Danaher for long-term value creation into 2026 and the future.
Danaher Corporation has shown robust performance in Q4 2025, characterized by positive revenue and earnings per share outcomes. Its dedication to innovation and enhancing human health illustrates a promising trajectory for sustained success.